Abstract

Purpose: To develop a non-invasive and quantitative information platform to accurately identify the prostate cancer foci and tumor aggressiveness grade. Methods: 11 patients who received magnetic resonance imaging (MRI) and magnetic resonance spectroscopy imaging (MRSI) prior to the surgery were studied. Multi-parametric imaging included extracting T2-map, Apparent Diffusion Coefficient (ADC) using diffusion weighted MRI, Ktrans using Dynamic Contrast Enhanced MRI, and 3D-MR Spectroscopy. Each image was composed of approximately 10 slices, which were divided into octants and individually assessed for the presence/absence of tumor by a radiologist. Following the radical prostatectomy, digital images of both the slice specimens and the histopathology slides were obtained. A pathologist reviewed all 223 octants and marked cancerous regions on each and graded them with Gleason score, which served as the ground truth to validate our prediction. Both binary prediction (indolent/aggressive cancer, separated by Gleason = 6) and multi-class prediction (no-cancer, non-aggressive cancer and aggressive cancer) were performed. Adaptive boosting with random under-sampling method was used. Area under the receiver operating characteristic (ROC) curve (AUC) and 95% confidence intervals were collected after repetitions of 10-fold cross-validation. Results: In binary prediction, average AUC value of was 0.77 [0.73, 0.79] with average sensitivity and specificity 79% [74%, 85%] and 74% [70%, 77%], respectively. For the multi-class classification, the average prediction accuracy for the no-cancer class was 97% [91%, 100%], for non-aggressive cancer class was 80% [76%, 83%] and for aggressive cancer class was 65% [59%, 72%]. The overall accuracy was 86% [83%, 88%]. Conclusion: We provided a sophisticated while user-friendly platform using multi-parametric MRI combined with supervised learning to be able to accurately detect cancer foci and its aggressiveness. In addition, our method was non-invasive and allowed for non-subjective disease characterization, which provided physician information to make personalized treatment decision.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.